My Treatment Approach: Chronic Lymphocytic Leukemia | Supplements and Featured Publications

June 15, 2021

Parameswaran Venugopal, MD, discussed the toxicity profiles of BTK inhibitors regarding treatment selection in CLL.

January 27, 2021

Tara Graff, DO, highlights active areas of exploration that are generating excitement in chronic lymphocytic leukemia.

November 18, 2020

Alan P. Z. Skarbnik, MD, breaks down factors that should be kept in mind when navigating the complex chronic lymphocytic leukemia armamentarium as it relates to BTK inhibitors.

November 17, 2020

Farrukh Awan, MD, discusses the importance of risk stratification in chronic lymphocytic leukemia.

November 17, 2020

Matthew Lunning, DO, discussed other key considerations for choosing treatments, continuous vs fixed-duration therapies, and emerging agents for patients with relapsed/ refractory CLL and SLL.

November 10, 2020

Matthew A. Lunning, DO, discusses initial treatment considerations in chronic lymphocytic leukemia.

November 10, 2020

Alexey V. Danilov, MD, PhD, discusses the role of disease biology in up-front treatment selection in chronic lymphocytic leukemia.

November 09, 2020

Alexey V. Danilov, MD, PhD, discusses BTK inhibitors and BCL-2 inhibitors that have led to a paradigm shift in the treatment of patients with chronic lymphocytic leukemia.

November 04, 2020

Farrukh Awan, MD, discusses the importance of collaborative care in chronic lymphocytic leukemia.

October 26, 2020

Alexey V. Danilov, MD, PhD, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.

October 23, 2020

Farrukh Awan, MD, discusses treatment options in the first relapsed setting in patients with chronic lymphocytic leukemia.